MRVI
Maravai LifeSciences Holdings, Inc.
Biotechnology
Market Cap$436M
5Y Perf.-91.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MRVI vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+461.1%
MRVI vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MRVI | NUVL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $436M | $7.53B |
| Revenue (TTM) | $186M | $0.00 |
| Net Income (TTM) | $-131M | $-450M |
| Gross Margin | 18.3% | — |
| Operating Margin | -115.9% | — |
| Total Debt | $36M | $0.00 |
| Cash & Equiv. | $217M | $262M |
MRVI vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MRVI
NUVL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Maravai LifeScience… (MRVI) | 100 | 9.0 | -91.0% |
| Nuvalent, Inc. (NUVL) | 100 | 561.1 | +461.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MRVI vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVL leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Maravai LifeSciences Holdings, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MRVI
Maravai LifeSciences Holdings, Inc.
The Growth Play
MRVI is the clearest fit if your priority is growth exposure.
- Rev growth -80.8%, EPS growth 77.1%, 3Y rev CAGR -61.6%
- +85.8% vs NUVL's +53.5%
Best for: growth exposure
NUVL
Nuvalent, Inc.
The Income Pick
NUVL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.09
- 446.1% 10Y total return vs MRVI's -86.8%
- Lower volatility, beta 1.09, current ratio 15.27x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs MRVI's -80.8% |
| Quality / Margins | NUVL | 3.2% margin vs MRVI's -70.4% |
| Stability / Safety | NUVL | Beta 1.09 vs MRVI's 2.03 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MRVI | +85.8% vs NUVL's +53.5% |
| Efficiency (ROA) | NUVL | -37.8% ROA vs MRVI's -187.0%, ROIC -32.5% vs -39.2% |
MRVI vs NUVL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
MRVI vs NUVL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVLLAGGINGMRVI
MRVIMaravai LifeSciences …
0leads
NUVLNuvalent, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MRVIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MRVI and NUVL operate at a comparable scale, with $186M and $0 in trailing revenue.
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $186M | $0 |
| EBITDAEarnings before interest/tax | -$230M | -$346M |
| Net IncomeAfter-tax profit | -$131M | -$450M |
| Free Cash FlowCash after capex | -$46M | -$313M |
| Gross MarginGross profit ÷ Revenue | +18.3% | — |
| Operating MarginEBIT ÷ Revenue | -115.9% | — |
| Net MarginNet income ÷ Revenue | -70.4% | — |
| FCF MarginFCF ÷ Revenue | -24.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -11.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -33.3% | -17.8% |
NUVL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MRVI and NUVL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| Market CapShares × price | $436M | $7.5B |
| Enterprise ValueMkt cap + debt − cash | $255M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -16.42x | -17.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.75x | — |
| Price / BookPrice ÷ Book value/share | 1.53x | 5.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MRVI and NUVL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — MRVI and NUVL each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
MRVI delivers a -35.1% return on equity — every $100 of shareholder capital generates $-35 in annual profit, vs $-43 for NUVL. On the Piotroski fundamental quality scale (0–9), MRVI scores 2/9 vs NUVL's 1/9, reflecting mixed financial health.
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -35.1% | -42.8% |
| ROA (TTM)Return on assets | -187.0% | -37.8% |
| ROICReturn on invested capital | -39.2% | -32.5% |
| ROCEReturn on capital employed | -25.7% | -34.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.10x | — |
| Net DebtTotal debt minus cash | -$181M | -$262M |
| Cash & Equiv.Liquid assets | $217M | $262M |
| Total DebtShort + long-term debt | $36M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -10.92x | -26.85x |
Evenly matched — MRVI and NUVL each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $1,061 for MRVI. Over the past 12 months, MRVI leads with a +85.8% total return vs NUVL's +53.5%. The 3-year compound annual growth rate (CAGR) favors NUVL at 39.5% vs MRVI's -34.3% — a key indicator of consistent wealth creation.
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +15.9% | +1.5% |
| 1-Year ReturnPast 12 months | +85.8% | +53.5% |
| 3-Year ReturnCumulative with dividends | -71.7% | +171.2% |
| 5-Year ReturnCumulative with dividends | -89.4% | +446.1% |
| 10-Year ReturnCumulative with dividends | -86.8% | +446.1% |
| CAGR (3Y)Annualised 3-year return | -34.3% | +39.5% |
NUVL leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MRVI and NUVL each lead in 1 of 2 comparable metrics.
Risk & Volatility
NUVL is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than MRVI's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRVI currently trades 96.0% from its 52-week high vs NUVL's 90.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 1.09x |
| 52-Week HighHighest price in past year | $4.11 | $113.02 |
| 52-Week LowLowest price in past year | $1.95 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +96.0% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 67.7 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 544K |
Evenly matched — MRVI and NUVL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MRVI as "Buy" and NUVL as "Buy". Consensus price targets imply 41.0% upside for NUVL (target: $144) vs 14.2% for MRVI (target: $5).
| Metric | MRVIMaravai LifeScien… | NUVLNuvalent, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.50 | $144.40 |
| # AnalystsCovering analysts | 14 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVL leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
Best OverallNuvalent, Inc. (NUVL)Leads 2 of 6 categories
Loading custom metrics...
MRVI vs NUVL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MRVI or NUVL a better buy right now?
Analysts rate Maravai LifeSciences Holdings, Inc.
(MRVI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MRVI or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to -89. 4% for Maravai LifeSciences Holdings, Inc. (MRVI). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus MRVI's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MRVI or NUVL?
By beta (market sensitivity over 5 years), Nuvalent, Inc.
(NUVL) is the lower-risk stock at 1. 09β versus Maravai LifeSciences Holdings, Inc. 's 2. 03β — meaning MRVI is approximately 86% more volatile than NUVL relative to the S&P 500.
04Which is growing faster — MRVI or NUVL?
On earnings-per-share growth, the picture is similar: Maravai LifeSciences Holdings, Inc.
grew EPS 77. 1% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MRVI or NUVL?
Nuvalent, Inc.
(NUVL) is the more profitable company, earning 0. 0% net margin versus -262. 2% for Maravai LifeSciences Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUVL leads at 0. 0% versus -431. 7% for MRVI. At the gross margin level — before operating expenses — MRVI leads at 25. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MRVI or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MRVI or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Nuvalent, Inc.
(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), +446. 1% 10Y return). Maravai LifeSciences Holdings, Inc. (MRVI) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUVL: +446. 1%, MRVI: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MRVI and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.